Prediction of s-glutathionylated proteins progression in alzheimer's transgenic mouse model using principle component analysis

Journal of Alzheimer's Disease

Volumn 30, Issue 4, 2012, Pages 919-934

  Zhang, Cheng ^a   Kuo, Ching Chang ^a   Chiu, Alan W L ^a   Feng, June ^a  

^a Louisiana Tech University   (United States)

Author keywords

Alzheimer's disease prediction; capillary gel electrophoresis with laser induced fluorescence detection (CGE LIF); principle component analysis (PCA); S glutathionylated proteins (Pr SSG)

Indexed keywords

PROTEIN; S GLUTATHIONYLATED PROTEIN; UNCLASSIFIED DRUG;

ALGORITHM; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN TISSUE; CAPILLARY ELECTROPHORESIS; CLASSIFICATION; CONTROLLED STUDY; DERIVATIZATION; DISEASE COURSE; EARLY DIAGNOSIS; EXPERIMENTAL MODEL; MOLECULAR WEIGHT; MOUSE; NEUROPATHOLOGY; NONHUMAN; NORMAL DISTRIBUTION; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROTEIN MODIFICATION; S GLUTATHIONYLATION; SCREENING; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; TRANSGENIC MOUSE;

EID: 84862979358     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120028     Document Type: Article

References (53)

1. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, TsuiW, Rusinek H (2004) MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 256, 205-223.
2. Klatt P, Lamas S (2000) Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 267, 4928-4944.
3. Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, Butterfield DA (2009) Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: Implications for AD pathogenesis. Neurochem Res 34, 727-733.
4. Zhang C, Rodriguez C, Circu ML, Aw TY, Feng J (2011) S-Glutathionyl quantification in the attomole range using glutaredoxin-3-catalyzed cysteine derivatization and capillary gel electrophoresis with laser-induced fluorescence detection. Anal Bioanal Chem 401, 2165-2175.
5. Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, Moller HJ, Hampel H (2007) Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage 38, 13-24.
6. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM,WeinerMW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B (2009) Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 132, 2048-2057.
7. Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, Puel M, Berry I, Fort JC, Celsis P (2009) Early diagnosis of Alzheimer's disease using cortical thickness: Impact of cognitive reserve. Brain 132, 2036-2047.
8. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379.
9. Kaplin A, Carroll KA, Cheng J, Allie R, Lyketsos CG, Calabresi P, Rosenberg PB (2009) IL-6 release by LPSstimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer's disease. Int Psychogeriatr 21, 413-414.
10. Mayeux R (2004) Biomarkers: Potential uses and limitations. NeuroRx 1, 182-188.
11. Jolliffe IT (2002) Principal Component Analysis, Springer-Verlag, New York Inc., New York.
12. Marsland S (2009) Machine Learning: An Algorithmic Perspective, Chapman and Hall/CRC, Boca Raton, Florida.
13. Johannesson N, Olsson L, Backstrom D, Wetterhall M, Danielsson R, Bergquist J (2007) Screening for biomarkers in plasma from patients with gangrenous and phlegmonous appendicitis using CE and CEC in combination with MS. Electrophoresis 28, 1435-1443.
14. Szymanska E, Markuszewski MJ, Capron X, van Nederkassel AM, Heyden YV, Markuszewski M, Krajka K, Kaliszan R (2007) Increasing conclusiveness of metabonomic studies by chem-informatic preprocessing of capillary electrophoretic data on urinary nucleoside profiles. J Pharm Biomed Anal 43, 413-420.
15. Feng J, Navratil M, Thompson LV, Arriaga EA (2008) Principal component analysis reveals age-related and muscletype-related differences in protein carbonyl profiles of muscle mitochondria. J Gerontol A Biol Sci Med Sci 63, 1277-1288.
16. Goto Y, Niidome T, Hongo H, Akaike A, Kihara T, Sugimoto H (2008) Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Eur J Pharmacol 583, 84-91.
17. Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS (2007) Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27, 7006-7010.
18. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13, 159-163.
19. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
20. Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24, 149-156.
21. Mehlhorn G, Hollborn M, Schliebs R (2000) Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 18, 423-431.
22. Musaro A, Rosenthal N (1999) Transgenic mouse models of muscle aging. Exp Gerontol 34, 147-156.
23. Parachikova A, Nichol KE, Cotman CW (2008) Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. Neurobiol Dis 30, 121-129.
24. Wirths O,Weis J, Kayed R, Saido TC, Bayer TA (2007) Agedependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 28, 1689-1699.
25. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue-amyloid peptide in vivo: Evidence for augmentation of a 42-specific c secretase. Hum Mol Genet 13, 159-170.
26. Zhang Q, Zhang X, Chen J, Miao Y, Sun A (2009) Role of caspase-3 in tau truncation at D421 is restricted in transgenic mouse models for tauopathies. J Neurochem 109, 476-484.
27. Monostori P, Wittmann G, Karg E, Turi S (2009) Determination of glutathione and glutathione disulfide in biological samples: An in-depth review. J Chromatogr B Analyt Technol Biomed Life Sci 877, 3331-3346.
28. Reynaert NL, Ckless K, Guala AS, Wouters EF, van der Vliet A, Janssen-Heininger YM (2006) In situ detection of S-glutathionylated proteins following glutaredoxin-1 catalyzed cysteine derivatization. Biochim Biophys Acta 1760, 380-387.
29. Hamnell-Pamment Y, Lind C, Palmberg C, Bergman T, Cotgreave IA (2005) Determination of site-specificity of S-glutathionylated cellular proteins. Biochem Biophys Res Commun 332, 362-369.
30. Cheng G, Ikeda Y, Iuchi Y, Fujii J (2005) Detection of S-glutathionylated proteins by glutathione S-transferase overlay. Arch Biochem Biophys 435, 42-49.
31. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82, 70-77.
32. Circu ML, Moyer MP, Harrison L, Aw TY (2009) Contribution of glutathione status to oxidant-induced mitochondrial DNA damage in colonic epithelial cells. Free Radic Biol Med 47, 1190-1198.
33. MacQueen J (1967) In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press 1, 281-297.
34. Franc V and Hlavac V (2004) Statistical Pattern Recognition Toolbox for Matlab, Czech Technical University, Prague.
35. Everitt BS (2006) The Cambridge Dictionary of Statistics, Cambridge University Press, Cambridge.
36. Kohavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence 2, 1137-1143.
37. Shao J (1993) Linear model selection by cross-validation. J Am Stat Assoc 88, 486-495.
38. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234.
39. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293, 1566-1570.
40. Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, Malorni W (2005) Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: A pilot study. FEBS Lett 579, 2759-2766.
41. Zhang C, Rodriguez C, Spaulding J, Aw TY, Feng J (2012) Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis 28, 655-666.
42. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, Klein JB, Turner DM, Butterfield DA (2007) An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85, 1506-1514.
43. Castegna A, AksenovM, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
44. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33, 562-571
45. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23, 655-664.
46. Teunissen CE, Lutjohann D, von Bergmann K, Verhey F, Vreeling F, Wauters A, Bosmans E, Bosma H, van Boxtel MP, Maes M, Delanghe J, Blom HJ, Verbeek MM, Rieckmann P, De Bruijn C, Steinbusch HW, de Vente J (2003) Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 24, 893-902.
47. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
48. Selkoe DJ (2000) The genetics and molecular pathology of Alzheimer's disease: Roles of amyloid and the presenilins. Neurol Clin 18, 903-922.
49. Link CD (2001) Transgenic invertebrate models of ageassociated neurodegenerative diseases. Mech Ageing Dev 122, 1639-1649.
50. Duff K, Suleman F (2004) Transgenic mouse models of Alzheimer's disease: Howuseful have they been for therapeutic development? Brief Funct Genomic Proteomic 3, 47-59.
51. Li L, Cheung T, Chen J, Herrup K (2011) A comparative study of five mouse models of Alzheimer's disease: Cell cycle events reveal new insights into neurons at risk for death. Int J Alzheimers Dis 2011, 171464.
52. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad SciUSA97, 2892-2897.
53. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47, 739-747.